USFDA grants orphan drug status to AstraZeneca's asthma drug Fasenra
AstraZeneca said on Wednesday that the U.S. Food and Drug Administration has granted orphan drug status to its severe asthma drug, Fasenra, to treat eosinophilic oesophagitis (EoE).
EoE, also known as allergic oesophagitis, is an allergic inflammation of the sophagus that involves a form of white blood cell, eosinophils.
Read Also:-AstraZeneca diabetes drug Farxiga meets goal in heart failure trial
AstraZeneca also separately said it met the main goal for its late-stage ETHOS trial for triple-drug therapy Breztri Aerosphere, formerly known as PT010, to treat moderate to very severe chronic obstructive pulmonary disease (COPD)
Read Also:-AstraZeneca gets USFDA fast track status for development of diabetes drug Farxiga
EoE, also known as allergic oesophagitis, is an allergic inflammation of the sophagus that involves a form of white blood cell, eosinophils.
Read Also:-AstraZeneca diabetes drug Farxiga meets goal in heart failure trial
AstraZeneca also separately said it met the main goal for its late-stage ETHOS trial for triple-drug therapy Breztri Aerosphere, formerly known as PT010, to treat moderate to very severe chronic obstructive pulmonary disease (COPD)
Read Also:-AstraZeneca gets USFDA fast track status for development of diabetes drug Farxiga
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd